Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy

Author(s): Dandan Tian and Zheyi Hu

Volume 15, Issue 8, 2014

Page: [808 - 817] Pages: 10

DOI: 10.2174/1389200216666150223152627

Price: $65

Abstract

Cytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.

Keywords: Anticancer drugs, cytochromes P450 (CYP) enzymes, drug-drug interactions, pharmacokinetics.


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy